An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies. - Findlay, Alison; Turner, Craig; Schilter, Heidi; Deodhar, Mandar; Zhou, Wenbin; Perryman, Lara; Foot, Jonathan; Zahoor, Amna; Yao, Yimin; Hamilton, Ross; Brock, Mary; Raso, Christina; et al. (Clinical & Translational Medicine, 2021)